ASKA Pharmaceutical Co., Ltd. announced consolidated earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported net sales of $116.5 million against $109.0 million a year ago. Operating income was $9.8 million against $4.2 million a year ago. Profit attributable of owners of parent was $9.5 million against $4.8 million a year ago.

For the second quarter ending September 2017, the company excepts nets sales of $227.3 million, operating income of $12.7 million and profit attributable to owners of parent of $11.8 million.

For the full year ending March 2018, the company excepts nets sales of $454.5 million, operating income of $18.2 million and profit attributable to owners of parent of $16.4 million.